Program

ABOUT THE BIOTECH CEO SUMMITS – UNLIKE ANY OTHER CONFERENCE

The Biotech CEO Summits are unlike most other meetings CEOs attend. The Summits focus on the participating CEOs discussing issues of importance to them as leaders of companies they want to position for growth and success. The Summits are discussion based meetings led by subject matter experts. All participants are invited to, and indeed encouraged to join the discussions by asking questions and sharing their personal insights. The Summits are run under Chatham House Rules to encourage open and frank conversation. The media are not invited, and the sessions are not recorded, to provide an extra layer of privacy.

2024 Agenda 

Monday, May 27

14:00

Registration: Main Lobby

16:30

Icebreaker Activity/Networking Reception: Dolce Vita Patio

Meet your fellow CEOs

18:45

Welcome & Opening Remarks: Dolce Vita Garden 

Sara Jane Demy, Founder & CEO, Demy-Colton

19:00

CEO Summit Participant Introductions: Dolce Vita Garden

19:30

Fireside Chat SeriesDolce Vita Garden

The Purposeful CEO – Fulfilling the Promise 

Biotech CEOs are committed to improving the health of patients. The path they take to fulfill their objective of delivering better health outcomes is challenging and requires risk-taking on many levels.

  • Moderator: Pankaj Oza, Managing Partner, Blue Matter
  • Fireside Chat CEO: Claudia Ulbrich, CEO, Cardior Pharmaceuticals
20:15

Networking Reception & Dinner: Terraza de la Taula

Tuesday, May 28

07:30

Private Networking Breakfast: Entre Venias Patio

08:30

Summit Overview & Rules of Engagement: Ra Conference Room
Sara Jane Demy
, Founder & CEO, Demy-Colton 

08:45

The Bioeconomy: Where Are We Today and Where Will We Be as We Head into 2025

With a change in the tides after a previously fractured economy, will the biotech sector in Europe keep its rightful place as a leader in innovation? Let’s discuss the predictions from our experts and consider how this will affect your company’s journey.

09:30

Fundraising:  Patience, Persistence, and Performance Pays in All Market Conditions

A discussion about building relationships with the investing community and potential partners that will lead to an investment or partnership to support your company. As well as what your company needs to consistently demonstrate to build confidence in your company.

10:15

Networking Break: Bamboo Garden 

10:30

The Path(s) Forward: Understanding the Strategic Options

Are you planning to go it alone, be acquired, or partner select assets? Let’s discuss various options to help advance your company.

11:15

For Successful BD and Fundraising: Every Company Has to Understand How Any Asset Will be Commercialized, Even at an Early Stage

It is critical for any company to demonstrate that they have a thorough understanding of how they will commercialize their assets, even at an early stage. Let’s explore strategies for successful product commercialization.

12:00

The Evolving Regulatory Environment:  Changes Underway in Europe and the US and How it Will Affect Market Access

The proposed European Parliament legislative overhaul designed to make Europe more attractive for the biopharma industry may not be so attractive, and, on the US side, is the IRA a Pandora’s box.

13:00

​​Networking Lunch: D.O. Terraza 

14:30

Market Access: Which Markets Are Right for Your Product and Company?

Often, EU companies that are planning for commercialization will target the US market because of its size and the fact that it is a single market while not targeting local markets or other regional markets. Let’s discuss the options and the resources and tactics for both.

15:15

Valuation Case Study Breakout: Art Rooms

16:00

Valuation Report Back: Ra Conference Room

16:30

Boards: The Psychological Challenge of the Board Meeting

Why do CEOs often dread these meetings? What are the dynamics? Fears?  We will discuss where you can find support as a CEO and overcome these hurdles.

17:15

Day 1 Wrap-Up & Instructions for Games

Sara Jane Demy, Founder & CEO, Demy-Colton

Sara Pinto, Managing Director, Program Development, Demy-Colton

17:30

Break

18:00

Biotech CEO Summit Europe Games: Entre Venias Patio

19:30

Break before Dinner

20:00

Biotech CEO Summit Europe Gala Dinner: Pool Deck

Welcome Remarks: Paula Burke, Director, Life Sciences & Healthcare, HSBC 

Wednesday, May 29

07:30

Private Networking Breakfast: Entre Venias Patio

08:45

Welcome Back & Day 2 Commences: Ra Conference Room

Sara Jane Demy, Founder & CEO, Demy-Colton 

09:00

Communication: A Tool to Achieve Your Corporate Goals 

Communication is critical for biotech companies because potential investors, partners and, ultimately, payers, doctors and patients will make their decisions based on two things: their awareness of the benefit of your product(s); and trust. We will explore the role of communication and its impact on achieving corporate goals, with a focus on external and internal alignment.

09:45

Off the Record Conversation About Your Board

Continuing yesterday’s conversation and learning from each other. 

10:30 Networking Break: Bamboo Garden 
11:00

Building a Smart Team & Keeping Them: The Essentials for Success

The team surrounding a CEO is critical to the success of the company. How do you assess the strengths of your team to understand its weaknesses to identify your needs?

11:45

Being a CEO Who Leads Through Difficult Times

A conversation with CEOs who have made it to the other side of countless challenges. What does it take personally and professionally to persevere and prosper in changing times.

12:30

An Unguarded Conversation Among Friends 

Is being a biotech CEO really the loneliest job in the world?  

13:15

Wrap Up Biotech CEO Summit   

Sara Jane Demy, Founder & CEO, Demy-Colton

13:30

Networking Luncheon and Closing: D.O. Terraza 

List of 2024 Discussants:

Renee Aguiar-Lucander, CEO, Calliditas Therapeutics AB
Paula Burke
, Director, Life Sciences & Healthcare, HSCB
Peter Feinstein
, Co-Founder, BioVentures Investors
Patrik Frei
, Founder & CEO, Venture Valuation AG
Juan Garcia, Managing Director, Biotechnology Business Institute
Eddie Gibson, Associate, Wickenstones Ltd
Ted Haack, Vice President, LatticePoint
Stephanie Léouzon, Managing Director & Vice Chair of European Healthcare, Stifel
Chris Maggos, Managing Director, Cohesion Bureau
Jeffrey Meckler, CEO, Indaptus Therapeutics, Inc.
Jeff Myers, Senior Vice President, Reimbursement Strategy and Market Access, Catalyst Healthcare Consulting (via Zoom)
Pankaj Oza, Managing Partner, Blue Matter
Joris Pezzini, EVP Biopharma, Alira Health 
Penny Sadler, Client Partner, Coulter Partners
Gretchen Schweitzer, Managing Director, Trophic Communications
Denise Scots-Knight, CEO, Mereo BioPharma
Thomas Tóth von Kiskér, CEO, Tillotts Pharma AG
Claudia Ulbrich, CEO, Cardior Pharmaceuticals
Wills Hughes Wilson, Chief Patient Access & Commercial Planning, Mereo BioPharma